Zura Bio Ltd
ZURABuild a strategy around ZURA
Zura Bio Ltd AI Insights
Informational only. Not investment advice.Snapshot
- Cash of 139M covers 2.6 years of burn at current -53.4M FCF TTM rate - runway extends into 2028 without dilution[Cash and Equivalents]
- Zero debt with 108M equity and 117M working capital - pristine balance sheet for pre-revenue biotech[Debt to Equity]
- R&D of 40.4M TTM is 56% of total opex (72.6M) - high science focus vs administrative overhead[Research and Development TTM]
Watch Triggers
- Cash and Equivalents: Falls below 80M (18-month runway) — Triggers dilutive financing risk; watch for shelf registrations
- Research and Development TTM: Increases >50% without pipeline news — Signals trial advancement or acceleration of burn rate
- Operating Expense TTM: G&A exceeds R&D spending — Would indicate capital misallocation away from science
Bull Case
EV of 301M with 139M cash means market values pipeline at only 162M - asymmetric upside if any program succeeds
2.6+ year runway without dilution provides time for clinical readouts; zero debt eliminates covenant risk
Bear Case
P/B of 4.1x on zero-revenue biotech - paying 4x book for unproven science with high failure probability
Burning 53.5M/year with no revenue path visible - entire investment thesis depends on clinical success
Bull vs Bear Balance
AI-generated sentiment analysis based on fundamental metrics and market conditions.
Leverage ZURA's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.
Forward Thesis
Binary clinical catalyst risk: pipeline success/failure will drive 2-5x moves in either direction
- Zero revenue means 100% valuation tied to pipeline
- EV of 301M implies market pricing specific probability of success
- Cash runway removes near-term financing overhang
Valuation Context
Caveats
ZURA Fundamentals
| Metric | Value | YoY Growth | Industry Percentile |
|---|---|---|---|
$356.24M | — | ||
$130.65M | — | ||
0.00 | — | ||
$0 | — | ||
$-1.09 | — | ||
0% | — | ||
0% | — | ||
$-72.75M | — | ||
-42.5% | +19.9% | — | |
Beta 5Y (Monthly) | unknown | — |
ZURA Dividend History
ZURA Stock Splits
ZURA SEC Filings
| Filing Date | Report Date | Report Type | Filing Link |
|---|---|---|---|
05/07/26 | 03/31/26 | 10-Q | |
03/19/26 | 12/31/25 | 10-K | |
11/13/25 | 09/30/25 | 10-Q | |
08/14/25 | 06/30/25 | 10-Q | |
05/08/25 | 03/31/25 | 10-Q | |
03/25/25 | 12/31/24 | 10-K | |
11/07/24 | 09/30/24 | 10-Q | |
08/13/24 | 06/30/24 | 10-Q | |
05/09/24 | 03/31/24 | 10-Q | |
03/25/25 | 12/31/23 | 10-K | |
03/28/24 | 12/31/23 | 10-K | |
11/13/23 | 09/30/23 | 10-Q | |
08/14/23 | 06/30/23 | 10-Q | |
05/12/23 | 03/31/23 | 10-Q | |
03/01/23 | 09/30/22 | 424B3 | |
10/25/22 | 06/30/22 | S-4/A | |
03/31/22 | 03/31/22 | 10-Q |